Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

December 2017

Webinar for Genetic Testing Authorization for Medicare Members


Harvard Pilgrim and AIM Specialty Health are hosting an additional webinar for providers who want to learn more about the genetic/genomic and molecular testing program for our Medicare Advantage members.

The webinar will be offered on Wednesday, Dec. 20th at noon. Registration is not required. For information and to connect to the meeting, please visit the webinar website.

Additional webinars will be offered in the first quarter of 2018, at which time we anticipate expanding the genetic testing authorization program to include our commercial members.

Overview of the genetic testing program

As we announced in the October issue of Network Matters, for dates of service beginning Jan. 1, 2018, Harvard Pilgrim is requiring prior authorization through AIM Specialty Health for genetic/genomic and molecular testing for our Medicare Advantage members, including:

  • Genetic testing for hereditary cardiac disease
  • Genetic testing for hereditary cancer susceptibility
  • Genetic testing for single-gene and multifactorial conditions
  • Pharmacogenetic and thrombophilia genetic testing
  • Reproductive carrier screening and prenatal diagnosis
  • Somatic tumor testing
  • Whole genome sequencing

Under this program, the ordering clinician is responsible for obtaining prior authorization through AIM Specialty Health. Providers may begin making prior authorization requests for genetic/genomic and molecular testing beginning Dec. 18, 2017.

Any genetic/genomic and molecular tests performed on or beyond Jan. 1, 2018 will not be reimbursed if a prior authorization was not obtained. To ensure that they are eligible for reimbursement, providers rendering these services should verify that the necessary prior authorization has been obtained prior to performing the test. Ordering providers should request prior authorization in one of the following ways:

More information

Please refer to our Stride (HMO) Medicare Advantage Molecular Diagnostic Management Medical Review Criteria and Molecular Diagnostic Management Authorization Policy for Stride for complete information.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

New Monthly Publication Date for Network Matters

New Policy: Maximum Dosages for Medical Drugs

Webinar for Genetic Testing Authorization for Medicare Members

New Medicare Beneficiary Identifier Coming in 2018

Methadone Maintenance Benefit Change in Massachusetts

Study Suggests Breastfed Babies Are Less Likely to Have Eczema as Teens

CLINICIAN CORNER

Changes to Premium Formulary for 2018

New Prior Authorization Policy for Radicava

Keytruda and Opdivo Prior Authorization Policies Updated

Depression Screening and Treatment

OFFICE ASSISTANT

Keep Panel Status and Demographic Information Up to Date

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Senior Vice President, Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator